CN111886253B - Pd-1激动剂抗体及其用途 - Google Patents

Pd-1激动剂抗体及其用途 Download PDF

Info

Publication number
CN111886253B
CN111886253B CN201980016779.7A CN201980016779A CN111886253B CN 111886253 B CN111886253 B CN 111886253B CN 201980016779 A CN201980016779 A CN 201980016779A CN 111886253 B CN111886253 B CN 111886253B
Authority
CN
China
Prior art keywords
antibody
seq
amino acid
acid sequence
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980016779.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN111886253A (zh
Inventor
柴清
丰意青
K·P·纽布恩
S·M·特鲁赫拉
P·韦尔迪诺
P·P·雅齐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to CN202411106929.2A priority Critical patent/CN118806891A/zh
Priority to CN202411106932.4A priority patent/CN118903407A/zh
Priority to CN202411106937.7A priority patent/CN118846042A/zh
Publication of CN111886253A publication Critical patent/CN111886253A/zh
Application granted granted Critical
Publication of CN111886253B publication Critical patent/CN111886253B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201980016779.7A 2018-03-02 2019-02-22 Pd-1激动剂抗体及其用途 Active CN111886253B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202411106929.2A CN118806891A (zh) 2018-03-02 2019-02-22 Pd-1激动剂抗体及其用途
CN202411106932.4A CN118903407A (zh) 2018-03-02 2019-02-22 Pd-1激动剂抗体及其用途
CN202411106937.7A CN118846042A (zh) 2018-03-02 2019-02-22 Pd-1激动剂抗体及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862637643P 2018-03-02 2018-03-02
US62/637643 2018-03-02
PCT/US2019/019076 WO2019168745A1 (en) 2018-03-02 2019-02-22 Pd-1 agonist antibodies and uses thereof

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202411106937.7A Division CN118846042A (zh) 2018-03-02 2019-02-22 Pd-1激动剂抗体及其用途
CN202411106932.4A Division CN118903407A (zh) 2018-03-02 2019-02-22 Pd-1激动剂抗体及其用途
CN202411106929.2A Division CN118806891A (zh) 2018-03-02 2019-02-22 Pd-1激动剂抗体及其用途

Publications (2)

Publication Number Publication Date
CN111886253A CN111886253A (zh) 2020-11-03
CN111886253B true CN111886253B (zh) 2024-08-27

Family

ID=65686121

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201980016779.7A Active CN111886253B (zh) 2018-03-02 2019-02-22 Pd-1激动剂抗体及其用途
CN202411106932.4A Pending CN118903407A (zh) 2018-03-02 2019-02-22 Pd-1激动剂抗体及其用途
CN202411106937.7A Pending CN118846042A (zh) 2018-03-02 2019-02-22 Pd-1激动剂抗体及其用途
CN202411106929.2A Pending CN118806891A (zh) 2018-03-02 2019-02-22 Pd-1激动剂抗体及其用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202411106932.4A Pending CN118903407A (zh) 2018-03-02 2019-02-22 Pd-1激动剂抗体及其用途
CN202411106937.7A Pending CN118846042A (zh) 2018-03-02 2019-02-22 Pd-1激动剂抗体及其用途
CN202411106929.2A Pending CN118806891A (zh) 2018-03-02 2019-02-22 Pd-1激动剂抗体及其用途

Country Status (26)

Country Link
US (1) US10493148B2 (https=)
EP (1) EP3759139A1 (https=)
JP (3) JP7071521B2 (https=)
KR (2) KR102536014B1 (https=)
CN (4) CN111886253B (https=)
AR (1) AR114127A1 (https=)
AU (2) AU2019228474B2 (https=)
BR (1) BR112020015983A2 (https=)
CA (1) CA3092064C (https=)
CL (1) CL2020002180A1 (https=)
CO (1) CO2020010188A2 (https=)
CR (1) CR20200375A (https=)
DO (1) DOP2020000153A (https=)
EA (1) EA202091809A1 (https=)
EC (1) ECSP20053544A (https=)
IL (1) IL276340A (https=)
JO (1) JOP20200210A1 (https=)
MA (1) MA52414A (https=)
MX (1) MX2020009124A (https=)
PE (1) PE20210045A1 (https=)
PH (1) PH12020551463A1 (https=)
SA (1) SA520420082B1 (https=)
SG (1) SG11202008437WA (https=)
TW (1) TWI708787B (https=)
WO (1) WO2019168745A1 (https=)
ZA (1) ZA202004601B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11207393B2 (en) * 2015-10-16 2021-12-28 President And Fellows Of Harvard College Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
CR20190550A (es) 2017-06-05 2020-04-05 Janssen Biotech Inc Anticuerpos que se unen específicamente a pd-1 y métodos de uso
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
CN116333126A (zh) * 2018-03-20 2023-06-27 上海药明生物技术有限公司 新型抗pd-1抗体
WO2020231882A2 (en) 2019-05-10 2020-11-19 The Regents Of The University Of California Modified pluripotent cells
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
EP4107189A4 (en) * 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH PD-1 AGONISTS OR IL-2 MUTEINS
BR112022021392A2 (pt) * 2020-04-22 2022-12-06 Igm Biosciences Inc Moléculas de ligação multiméricas de agonista de pd-1
EP4159235A4 (en) * 2020-05-25 2024-07-10 Foundation for Biomedical Research and Innovation at Kobe PHARMACEUTICAL COMPOSITION CONTAINING PD-1 AGONIST FOR TREATING OR PREVENTING TH2-MEDIATED DISEASE
BR112022023989A2 (pt) 2020-05-26 2023-02-07 Boehringer Ingelheim Int Anticorpos anti-pd-1
IL307887A (en) 2021-05-13 2023-12-01 Foundation For Biomedical Res And Innovation At Kobe Anti-human pd-1 agonist antibody and pharmaceutical composition comprising the antibody for treating or preventing inflammatory diseases
PE20241755A1 (es) 2021-11-19 2024-08-28 Mirobio Ltd Anticuerpos pd-1 disenados por ingenieria y usos de estos
JP2025504020A (ja) * 2022-01-28 2025-02-06 ジョージアミューン・インコーポレイテッド Ｐｄ－１アゴニストであるプログラム細胞死タンパク質１に対する抗体
WO2023200796A1 (en) * 2022-04-13 2023-10-19 The Regents Of The University Of California Immune cell inhibition by immune checkpoint engagers
WO2024010861A2 (en) * 2022-07-06 2024-01-11 Santa Ana Bio, Inc. Methods and compositions for treating autoimmune, allergic and inflammatory diseases
WO2024040206A2 (en) * 2022-08-19 2024-02-22 Eli Lilly And Company Pd-1 agonist antibodies and methods of treating autoimmune diseases with a pd-1 agonist antibody
WO2024050421A2 (en) * 2022-08-30 2024-03-07 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting programmed cell death protein 1 (pd-1)
WO2024092031A1 (en) 2022-10-25 2024-05-02 Seismic Therapeutic, Inc. VARIANT IgG FC POLYPEPTIDES AND USES THEREOF
CN116284447A (zh) * 2023-02-20 2023-06-23 苏州大学 一种靶向pd1嵌合抗原受体修饰的调节性t细胞及其制备方法与应用
TW202500583A (zh) * 2023-03-17 2025-01-01 美商美國禮來大藥廠 Pd-1促效劑抗體及以pd-1促效劑抗體治療發炎或自體免疫皮膚疾病之方法
WO2025042732A1 (en) * 2023-08-18 2025-02-27 Eli Lilly And Company Pd-1 agonist antibodies and methods of treating autoimmune diseases with a pd-1 agonist antibody
CN120424213A (zh) * 2024-02-02 2025-08-05 英诺湖医药(杭州)有限公司 特异性结合pd-1的单克隆抗体及其医药用途
WO2026008664A1 (en) 2024-07-01 2026-01-08 Vib Vzw Allosteric modulators of inhibitory immune receptor complexes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2742953A1 (en) * 2011-08-11 2014-06-18 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
US20120269806A1 (en) 2007-08-21 2012-10-25 The General Hospital Corporation Methods of inducing tolerance
JP5794917B2 (ja) 2008-09-12 2015-10-14 アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ Ｐｄ−１特異抗体およびその使用
US8927697B2 (en) 2008-09-12 2015-01-06 Isis Innovation Limited PD-1 specific antibodies and uses thereof
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
US20130202623A1 (en) 2010-02-16 2013-08-08 Nicolas Chomont Pd-1 modulation and uses thereof for modulating hiv replication
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN105431449B (zh) 2013-04-05 2021-08-24 港大科桥有限公司 新的pd1同种型及其用于加强免疫应答的用途
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
WO2016020856A2 (en) * 2014-08-05 2016-02-11 MabQuest SA Immunological reagents
HK1254803A1 (zh) 2015-06-23 2019-07-26 Memorial Sloan Kettering Cancer Center 新型pd -1的免疫调节剂
EA201890790A1 (ru) * 2015-09-29 2018-10-31 Селджин Корпорейшн Связывающие pd-1 белки и способы их применения
PL3368572T3 (pl) 2015-10-02 2022-09-12 Symphogen A/S Przeciwciała anty-PD-1 oraz kompozycje
CR20180151A (es) 2015-10-02 2018-05-25 Hoffmann La Roche Antcuierpos anti-pd1 y métodos de uso
KR102809728B1 (ko) 2015-12-02 2025-05-21 주식회사 에스티큐브 글리코실화된 pd-1에 대해 특이적인 항체 및 이의 사용 방법
CR20190550A (es) 2017-06-05 2020-04-05 Janssen Biotech Inc Anticuerpos que se unen específicamente a pd-1 y métodos de uso

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2742953A1 (en) * 2011-08-11 2014-06-18 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist

Also Published As

Publication number Publication date
CO2020010188A2 (es) 2020-08-31
BR112020015983A2 (pt) 2020-12-15
AU2019228474B2 (en) 2023-04-13
IL276340A (en) 2020-09-30
CL2020002180A1 (es) 2021-01-04
US10493148B2 (en) 2019-12-03
AU2019228474A1 (en) 2020-08-20
ZA202004601B (en) 2022-03-30
EA202091809A1 (ru) 2020-11-23
AR114127A1 (es) 2020-07-22
KR20200115614A (ko) 2020-10-07
TW201942133A (zh) 2019-11-01
JP2022088411A (ja) 2022-06-14
CN111886253A (zh) 2020-11-03
CN118806891A (zh) 2024-10-22
AU2023204569A1 (en) 2023-10-26
KR102536014B1 (ko) 2023-05-24
SA520420082B1 (ar) 2022-11-11
WO2019168745A1 (en) 2019-09-06
ECSP20053544A (es) 2020-10-30
MA52414A (fr) 2021-01-06
JP2021516235A (ja) 2021-07-01
NZ766604A (en) 2024-10-25
CN118846042A (zh) 2024-10-29
MX2020009124A (es) 2020-09-28
TWI708787B (zh) 2020-11-01
SG11202008437WA (en) 2020-09-29
JP7071521B2 (ja) 2022-05-19
CA3092064A1 (en) 2019-09-06
PE20210045A1 (es) 2021-01-08
JP2023093549A (ja) 2023-07-04
CN118903407A (zh) 2024-11-08
KR20230079458A (ko) 2023-06-07
JP7259107B2 (ja) 2023-04-17
PH12020551463A1 (en) 2021-09-01
EP3759139A1 (en) 2021-01-06
CA3092064C (en) 2024-01-02
US20190270818A1 (en) 2019-09-05
JOP20200210A1 (ar) 2020-08-30
DOP2020000153A (es) 2020-09-15
CR20200375A (es) 2020-09-25

Similar Documents

Publication Publication Date Title
CN111886253B (zh) Pd-1激动剂抗体及其用途
US12258411B2 (en) Anti-CCR8 antibodies and uses thereof
US20240409655A1 (en) Anti-ox40 antibodies and methods of use
EP3081576B1 (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI790548B (zh) 抗人類cd19抗體
US12606619B2 (en) Human monoclonal antibodies against TIGIT for immune related diseases
CN114641500B (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法
WO2021098748A1 (en) Methods of cancer treatment with anti-ox40 antibody in combination with chemotherapeutic agents
JP2025539796A (ja) Ｌａｇ－３およびｐｄ－１／ｌａｇ－３抗体
EA044114B1 (ru) Агонистические антитела против pd-1 и их применение
EA048356B1 (ru) МУЛЬТИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К EGFRxCD28

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant